Amylin, Lilly and Alkermes have joined forces to get exenatide once weekly, a subcutaneous injection of exenatide for the treatment of type 2 diabetes on the market. The drug is in a grouping of many new longer lasting type 2 diabetes treatment drugs that have had effective results without the risk of hypoglycemia. Exenatide could be approved on Friday, March 12 after a 5-day interruption by the Food and Drug Administration for weather-related problems.
The new exenatide is the answer to millions of type 2 diabetes patients who are unable to control their blood sugar with daily insulin injections. The side effects from the drug are extensive, but most diabetes treatment drugs cause similar issues, such as stomach problems, dizziness, jittery feelings, skin irritation and decreased urination.